Page last updated on July 16, 2024
Forte Biosciences, Inc. reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2024-03-18 16:20:35 EDT.
Filings
10-K filed on 2024-03-18
Forte Biosciences, Inc. filed a 10-K at 2024-03-18 16:20:35 EDT
Accession Number: 0000950170-24-032843
Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!
Item 1C. Cybersecurity.
Item 1C. Cybersecurity. We have implemented and maintain processes designed to identify, assess and manage material risks from cybersecurity threats to our computer networks, third party hosted services, communications systems, hardware and software, and our data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and personal information of employees and others (“Information Systems and Data”). Our information technology consultants help identify, assess and manage the Company’s cybersecurity threats and risks. Our information technology consultants identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example: manual and automated cybersecurity tools such as malware scans and; vulnerability testing. Depending on the environment, we implement and maintain technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate risks from cybersecurity threats to our Information Systems and Data, including, for example: employee training; access controls; data encryption; systems monitoring; regular patching of operating systems and software; and a password policy. Our assessment and management of material risks from cybersecurity threats are integrated into the Company’s overall risk management processes. For example, our information technology consultants work with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business. We use third-party service providers to perform a variety of functions throughout our business, such as electronic communications service providers, cloud-based file storage service providers, and contract manufacturing and research organizations. 52 We evaluate the cybersecurity posture of such third-party service providers, including whether such providers maintain appropriate security measures and, where appropriate, require them to implement and maintain reasonable security measures in connection with their work with us. Our Board, as a whole and at the committee level, has oversight for the most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks. The Audit Committee, which is comprised solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Audit Committee receives updates, as needed, on cybersecurity and information technology matters and related risk exposures from our Chief Financial Officer as well as other members of the senior leadership team. The Board also receives updates from management and the Audit Committee on cybersecurity risks. For additional information regarding whether any risks from cybersecurity threats are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to Item 1A, “Risk Factors” in this Annual Report on Form 10-K.
Company Information
Name | Forte Biosciences, Inc. |
CIK | 0001419041 |
SIC Description | Pharmaceutical Preparations |
Ticker | FBRX - Nasdaq |
Website | |
Category | Non-accelerated filer Smaller reporting company |
Fiscal Year End | December 30 |